Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01284608
NCT01284608
Completed
Not Applicable

Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)

AstraZeneca1 site in 1 country197 target enrollmentMarch 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstatic Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostatic Cancer
Sponsor
AstraZeneca
Enrollment
197
Locations
1
Primary Endpoint
Metabolic syndrome
Status
Completed
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Registry
clinicaltrials.gov
Start Date
March 2011
End Date
December 2012
Last Updated
13 years ago
Study Type
Observational
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment
  • •Provision of informed consent prior to conducting any study-related procedure

Exclusion Criteria

  • •Patient involved in a Clinical Trial

Outcomes

Primary Outcomes

Metabolic syndrome

Time Frame: 12 months

Diabetes

Time Frame: 12 months

Secondary Outcomes

  • Fracture Risk Assessment Tool (FRAx) assessment(0 and 12 months)

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Prostate Metabolism, Cancer Risk and Gut MicrobiotaProstate CancerProstate Hyperplasia
NCT06116851Turku University Hospital300
Unknown
Not Applicable
Fasting Mimicking Diet in Prostate Cancer and Metabolic SyndromeProstate CancerMetabolic SyndromeIntermittent Fasting
NCT04292041Galway Clinic40
Completed
Not Applicable
A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in ItalyProstate Cancer
NCT05759273Ipsen167
Recruiting
Not Applicable
Metabolomics of prostate cancer patients to identify diagnostic and prognostic biomarkersHealth Condition 1: C61- Malignant neoplasm of prostate
CTRI/2023/01/048921AIIMS New Delhi
Completed
Phase 2
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 TherapyProstate Cancer
NCT03062254Sir Mortimer B. Davis - Jewish General Hospital14